List of Excipients in Branded Drug DESVENLAFAXINE ER

Generic Drugs Containing DESVENLAFAXINE ER

Company	Ingredient	NDC	Excipient
Direct_Rx	desvenlafaxine er	61919-882	CELLULOSE, MICROCRYSTALLINE
Direct_Rx	desvenlafaxine er	61919-882	FERRIC OXIDE RED
Direct_Rx	desvenlafaxine er	61919-882	FERRIC OXIDE YELLOW
Direct_Rx	desvenlafaxine er	61919-882	HYPROMELLOSES
Direct_Rx	desvenlafaxine er	61919-882	MAGNESIUM STEARATE
Direct_Rx	desvenlafaxine er	61919-882	POLYETHYLENE GLYCOL 3350

What are the Most Frequently-Used Excipients in DESVENLAFAXINE ER?

# Of NDCs	Excipient
2	CELLULOSE, MICROCRYSTALLINE
1	FD&C RED NO. 40
1	FD&C YELLOW NO. 6
1	FERRIC OXIDE RED
1	FERRIC OXIDE YELLOW
1	HYPROMELLOSE

Desvenlafaxine ER Excipient Strategy and Commercial Opportunities

Last updated: August 9, 2026

Desvenlafaxine extended-release, marketed as Pristiq and supplied by multiple generic manufacturers, is a mature oral solid-dose product with limited active-ingredient exclusivity but continuing formulation and manufacturing opportunities. The most attractive commercial positions are controlled-release excipient systems, low-cost direct-compression platforms, differentiated strengths and pack sizes, and 505(b)(2) products that improve administration or adherence without relying on a conventional generic strategy.

Desvenlafaxine is the active metabolite of venlafaxine and is approved in the United States for major depressive disorder. The reference product is a once-daily, non-scored, film-coated extended-release tablet containing desvenlafaxine succinate equivalent to 25 mg, 50 mg, or 100 mg of desvenlafaxine.[1]

What excipients are used in desvenlafaxine ER tablets?

The reference product uses a relatively conventional hydrophilic matrix and film-coating system. Public labeling identifies microcrystalline cellulose, hypromellose, talc, magnesium stearate, polyvinyl alcohol, titanium dioxide, polyethylene glycol and iron oxides among the inactive ingredients.[1]

Excipient or excipient class	Primary function in desvenlafaxine ER	Commercial relevance
Hypromellose	Hydrophilic release-control polymer and tablet binder	Core technology for matching dissolution
Microcrystalline cellulose	Filler, dry binder and compression aid	Supports robust direct compression
Magnesium stearate	Lubricant	Excess use can slow wetting and dissolution
Talc	Glidant, anti-adherent and coating aid	Supports manufacturing and film-coat performance
Polyvinyl alcohol	Film-forming polymer	Enables protective and cosmetic coating
Polyethylene glycol	Plasticizer and coating-process aid	Controls film flexibility
Titanium dioxide	Opacifier and colorant	May require reformulation in markets restricting titanium dioxide
Iron oxides	Color differentiation by strength	Supports product identification and packaging controls

The product is swallowed whole. The FDA label specifically instructs patients not to divide, crush, chew or dissolve the tablet because these actions can affect extended release.[1]

The key formulation challenge is not simply tablet hardness. It is controlling the release profile across the gastrointestinal tract while maintaining content uniformity, mechanical strength, stability and bioequivalence. A formulation that releases desvenlafaxine too quickly can create an unacceptable dissolution or pharmacokinetic profile. A matrix that is too resistant can reduce exposure or create sensitivity to food, agitation and manufacturing variation.

How does the desvenlafaxine ER release mechanism work?

Desvenlafaxine ER is generally approached as a hydrophilic matrix tablet. After ingestion, water penetrates the tablet, hypromellose hydrates and forms a gel layer, and the drug diffuses through or is released as the matrix erodes.

The main formulation variables are:

1. Hypromellose grade and viscosity.
2. Polymer concentration relative to drug load.
3. Particle-size distribution of the active ingredient.
4. Tablet porosity and compression force.
5. Lubricant level and blending time.
6. Coating weight gain and film permeability.
7. Dissolution performance across pH conditions.

Higher-viscosity hypromellose can slow release but may increase processing difficulty, tablet swelling and batch-to-batch sensitivity. Lower-viscosity grades improve processing and may produce faster release, but they can provide less control at later dissolution time points.

A practical generic platform usually combines a moderate-viscosity hypromellose grade with microcrystalline cellulose and controlled compression. The objective is to produce a robust matrix without excessive dependence on specialized equipment or proprietary excipients.

What formulation strategies are available for desvenlafaxine ER?

Hydrophilic matrix tablets

The lowest-risk commercial route is a conventional hydrophilic matrix. This approach has a broad supplier base, established regulatory precedent and relatively low manufacturing cost.

Key development work includes:

• Screening hypromellose viscosity grades.
• Mapping polymer concentration against dissolution.
• Controlling granule or blend density.
• Establishing discriminatory dissolution methods.
• Evaluating dose proportionality across 25 mg, 50 mg and 100 mg strengths.
• Testing alcohol sensitivity and mechanical abuse conditions.
• Demonstrating stability under accelerated and long-term conditions.

The principal weakness is low differentiation. A standard matrix tablet is well suited to an ANDA but offers limited composition-of-matter protection unless the formulation has a patentable release system or manufacturing process.

Direct-compression formulation

Direct compression can reduce processing steps, solvent use and capital requirements. Microcrystalline cellulose, a suitable hypromellose grade and a carefully selected lubricant system can support production without wet granulation.

The main risks are segregation, poor flow, tablet-weight variation and sensitivity to active-particle morphology. Desvenlafaxine succinate loading is not so high that direct compression is technically implausible, but the formulation must maintain uniformity across commercial-scale hoppers and feeders.

Direct compression is commercially attractive for contract manufacturers and regional generic companies because it can reduce conversion cost and simplify technology transfer.

Wet-granulated matrix

Wet granulation can improve flow, compressibility and content uniformity. It may be useful where the active ingredient has poor flow or where a high-throughput tableting line produces unacceptable weight variation.

The tradeoffs are greater process complexity, residual-moisture control and potential changes in polymer hydration. Granulation can also alter dissolution by changing porosity and the distribution of hypromellose within the tablet.

Multiparticulate or coated-pellet systems

A multiparticulate formulation could use drug-loaded pellets coated with a rate-controlling polymer and filled into capsules or compressed into a tablet. This design may provide more control over dose distribution and can support alternative administration concepts.

It is less attractive for a conventional generic because it adds manufacturing cost and increases bioequivalence risk. It becomes more commercially relevant under a 505(b)(2) strategy involving a new dosage form, sprinkle product or modified administration method.

Film-coating reformulation

Film-coating changes can address color, swallowability, coating defects, titanium dioxide restrictions or supply-chain problems. A coating-only change usually has limited commercial value unless it solves a market-access or manufacturing issue.

Potential opportunities include:

• Titanium-dioxide-free coatings.
• Lower-friction coatings that improve high-speed packaging.
• Color systems that reduce medication errors.
• Moisture-barrier coatings for humid markets.
• Thinner coatings that lower material cost.
• Coatings optimized for automated visual inspection.

A coating reformulation must not alter release, stability or tablet handling in a way that creates regulatory comparability problems.

What generic and 505(b)(2) opportunities exist for desvenlafaxine ER?

The conventional generic opportunity is established. FDA approved the first generic versions of Pristiq in 2017, and desvenlafaxine ER is now supplied through multiple ANDA holders.[2] The market is therefore characterized by price competition, pharmacy-channel access and manufacturing efficiency rather than by broad patent exclusivity.

Conventional ANDA opportunity

A standard ANDA requires pharmaceutical equivalence and bioequivalence to the reference listed drug. Commercial success depends on:

• Approval timing relative to competing applicants.
• Ability to manufacture all marketed strengths.
• Reliable active-pharmaceutical-ingredient supply.
• Low tablet conversion cost.
• Stable dissolution performance.
• National wholesaler and pharmacy contracts.
• Freedom from manufacturing interruptions.

The 50 mg strength is likely to be the commercial anchor because it is the usual starting and maintenance strength in the prescribing information.[1] The 25 mg strength is used for initiation and tapering, while the 100 mg strength is available when clinically indicated. A supplier offering only one strength may face limited formulary leverage.

505(b)(2) opportunity

A 505(b)(2) product could pursue a differentiated dosage form or administration method. Candidate concepts include:

• Smaller tablets for patients with swallowing difficulty.
• Sprinkle or capsule-based delivery.
• Alternative release profiles.
• Orally disintegrating or rapidly dispersing systems, subject to preservation of extended release.
• Packaging designed for adherence and dose titration.
• A lower-dose presentation for tapering protocols.
• A product addressing excipient intolerance or regional excipient restrictions.

A 505(b)(2) strategy has greater development cost and regulatory complexity than an ANDA. Its value depends on whether the product solves a clinically relevant administration problem rather than merely changing excipients.

What patents protect desvenlafaxine ER products?

Desvenlafaxine patent protection has historically included patents directed to the active compound, salts, formulations and therapeutic use. The principal U.S. exclusivity period for the original product has expired, and generic entry has occurred.[2][3]

The original innovator was Wyeth, later part of Pfizer. Historical Orange Book listings for Pristiq included patents associated with desvenlafaxine and its use. The FDA Orange Book remains the controlling public source for listed patents, patent delistings and product-specific exclusivity information.[3]

Protection category	Strategic relevance today
Active compound or metabolite patent	Generally expired or commercially exhausted in the U.S.
Desvenlafaxine succinate salt or solid form	May affect historical entry timing; must be checked by jurisdiction
Extended-release formulation	Relevant to dissolution and formulation design
Method-of-use patent	May affect specific indications or dosing claims
Manufacturing process	Can create freedom-to-operate issues even after product patents expire
New dosage-form patent	Potential basis for 505(b)(2) differentiation
Excipient composition patent	Potentially valuable if the system creates a demonstrable release or stability benefit

Excipient selection itself is rarely sufficient for meaningful patent protection. A stronger patent position usually requires a defined polymer system, quantitative compositional ranges, dissolution limitations, process parameters or a clinical advantage tied to the formulation.

When did desvenlafaxine ER lose exclusivity?

U.S. generic competition began after the expiry of key Pristiq exclusivity and patent barriers. FDA approved generic desvenlafaxine ER applications in 2017, including products from major generic manufacturers.[2] The commercial market is therefore post-exclusivity in the United States.

The relevant timing questions now concern individual product patents, regulatory exclusivity and jurisdiction-specific rights rather than basic U.S. composition-of-matter protection. A company developing a new formulation must evaluate:

• Current Orange Book listings.
• Patent term adjustment and patent term extension.
• Any pediatric exclusivity.
• Litigation settlements.
• Product-specific labeling rights.
• Foreign patent status.
• Manufacturing patents owned by third parties.

What is the Orange Book status of desvenlafaxine ER?

The Orange Book lists approved drug products, therapeutic equivalence information and, where applicable, patents and exclusivity associated with reference products.[3] Desvenlafaxine ER generic products are generally evaluated against Pristiq as the reference listed drug.

Orange Book review should distinguish:

• The reference listed drug.
• Therapeutically equivalent generic products.
• Strength-specific approvals.
• Patent listings associated with the reference product.
• Whether a listed patent has expired or been removed.
• Whether an ANDA applicant made a Paragraph IV certification.

Because Orange Book entries change, a commercial launch decision should use the current FDA database rather than historical patent summaries.

How do Paragraph IV challenges affect desvenlafaxine ER?

Paragraph IV certifications are most relevant during the period when a listed patent remains active and an ANDA applicant asserts that the patent is invalid, unenforceable or not infringed. A timely patent-infringement action can trigger a 30-month stay of FDA approval under the Hatch-Waxman framework, subject to statutory exceptions.[4]

For a mature product such as desvenlafaxine ER, the principal Paragraph IV risk has shifted from basic generic entry to later-added formulation, use or manufacturing patents. A company considering a new excipient system should assess whether its design could infringe:

• Quantitative polymer-range claims.
• Controlled-release matrix claims.
• Specific salt or solid-form claims.
• Coating or barrier-layer claims.
• Manufacturing sequence claims.
• Method-of-use claims tied to once-daily dosing.

A non-infringement position based solely on changing one excipient may be weak if the patent claims the functional release architecture rather than the ingredient identity.

What manufacturing and excipient barriers affect commercial entry?

The active ingredient is generally available from multiple qualified sources, but supplier qualification remains a central risk. Desvenlafaxine succinate can create development variability through differences in particle size, bulk density, water content, polymorphic or solid-state characteristics and electrostatic behavior.

Important manufacturing controls include:

• API particle-size specifications.
• Moisture and hygroscopicity controls.
• Blend uniformity.
• Lubrication time.
• Compression-force ranges.
• Tablet tensile strength.
• Coating weight gain.
• In-process dissolution.
• Packaging moisture protection.

Excipient supply is less concentrated than API supply, but hypromellose remains a critical material. Changes in polymer viscosity grade, substitution pattern or supplier manufacturing process can alter dissolution. A robust supplier strategy should qualify at least two sources where feasible and establish material attributes linked directly to release performance.

How strong is the patent estate for desvenlafaxine ER?

The legacy patent estate is commercially weak for blocking standard U.S. generic tablets because generic products are already approved. The stronger opportunity lies in new formulation claims that produce measurable performance differences.

Patent strategy	Likely strength	Commercial use
Broad claim to desvenlafaxine ER	Low for new U.S. entry	Likely vulnerable to prior art and existing approvals
Specific hypromellose composition	Moderate if narrowly defined	Protects a differentiated matrix
Multiparticulate release system	Moderate to strong	Supports 505(b)(2) positioning
Excipient-free or titanium-dioxide-free design	Low unless tied to performance	Supports regulatory or supply-chain differentiation
Manufacturing process	Moderate	Can protect cost or scale advantages
Improved adherence or administration method	Moderate if clinically supported	Supports product differentiation
Specific patient population or tapering method	Variable	May support method-of-use protection

Patent value depends on claim breadth, prior-art exposure, enablement, enforceability and the commercial importance of the protected feature. An excipient patent that covers a narrow composition but does not improve bioequivalence, stability or patient use may have limited licensing value.

Which companies compete in desvenlafaxine ER?

Competition includes Pfizer as the reference-product sponsor and multiple generic manufacturers approved through the ANDA pathway. Generic competition is typically fragmented across large multinational companies, specialty generic companies and contract manufacturers.

Competitive advantages are likely to come from:

• Lower cost of goods.
• Consistent supply.
• Full-strength portfolio coverage.
• Strong wholesaler access.
• Reliable serialization and packaging.
• International registrations.
• Dual-source excipient and API procurement.
• Ability to offer private-label or regional products.

The market does not have a biosimilar pathway because desvenlafaxine is a small-molecule drug. Biosimilar risk is therefore irrelevant. The relevant substitutes are venlafaxine ER, duloxetine, selective serotonin reuptake inhibitors and other antidepressants, not biologic competitors.

What revenue exposure and commercial opportunities remain?

The original branded revenue opportunity is limited by generic substitution. Commercial value remains in four areas.

Low-cost generic supply

A manufacturer with efficient direct compression, high equipment utilization and reliable API sourcing can compete on gross margin even in a mature market. Multi-strength production improves purchasing leverage and reduces packaging complexity.

Regional and private-label distribution

Some markets have fewer approved suppliers than the United States. A company can create value through local registration, government tenders, pharmacy chains and private-label arrangements. Geographic patent and regulatory review remains necessary because generic availability is not uniform across countries.

Differentiated administration

A smaller tablet, adherence package or alternative dosage form can command better pricing if it addresses a defined patient or caregiver problem. The regulatory pathway and clinical value must justify the added development cost.

Excipient and technology licensing

A controlled-release platform can be licensed for desvenlafaxine and other once-daily small molecules. The strongest platform opportunities have transferable know-how in polymer selection, scale-up, dissolution control and coating technology.

What generic launch scenarios exist for desvenlafaxine ER?

The most likely launch scenarios are:

1. Standard multisource generic entry with aggressive price competition.
2. Regional launch focused on one or two strengths.
3. Private-label supply using an existing approved formulation.
4. 505(b)(2) launch with a differentiated dosage form.
5. Technology licensing to a generic company with commercial access.
6. Reformulation to address excipient restrictions or supply instability.

The least attractive strategy is a minor excipient substitution with no regulatory, clinical or manufacturing advantage. Such a product may require development work while remaining exposed to immediate generic price competition.

Key Takeaways

• Desvenlafaxine ER is a mature small-molecule product with established U.S. generic competition.
• The reference formulation relies on a conventional hydrophilic matrix, film coating and widely available excipients.
• Hypromellose grade, polymer concentration, tablet porosity and lubrication are the main release-control variables.
• Direct compression offers the clearest cost-reduction opportunity.
• A standard excipient change has limited commercial value unless it improves dissolution, stability, manufacturing or administration.
• The legacy U.S. patent estate is less important than new formulation, process and method-of-use claims.
• 505(b)(2) opportunities require a clinically relevant dosage-form or administration advantage.
• Biosimilar competition does not apply.
• The strongest commercial positions are low-cost multisource supply, differentiated delivery, regional registration and transferable controlled-release technology.

FAQs About Desvenlafaxine ER Excipients and Commercial Strategy

Can hypromellose be replaced in a desvenlafaxine ER formulation?

Yes, but replacement can materially change hydration, gel strength and dissolution. Any substitute requires formulation redevelopment and comparative performance testing.

Is desvenlafaxine ER suitable for an orally disintegrating tablet?

An orally disintegrating format is technically possible but difficult because extended release must be preserved. A multiparticulate or coated-pellet approach may be more suitable than a conventional rapidly disintegrating matrix tablet.

Does changing the film coating avoid desvenlafaxine patents?

Not automatically. Patent claims may cover the core matrix, release profile, process or method of use rather than the external coating.

Can a titanium-dioxide-free desvenlafaxine tablet support a new product?

It can support a formulation or supply-chain project, particularly in jurisdictions with titanium dioxide restrictions. It usually does not create strong commercial differentiation without an accompanying regulatory, stability or patient-use benefit.

What is the most attractive desvenlafaxine ER licensing asset?

A scalable controlled-release platform with demonstrated bioequivalence, broad excipient sourcing, strong dissolution control and applicability to multiple small-molecule products is generally more valuable than a narrow single-product excipient substitution.

References

1. U.S. Food and Drug Administration. (2023). Pristiq (desvenlafaxine) extended-release tablets: Prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/021992s044lbl.pdf

2. U.S. Food and Drug Administration. (2017). FDA approves first generic versions of Pristiq to treat depression. https://www.fda.gov/news-events/press-announcements/fda-approves-first-generic-versions-pristiq-treat-depression

3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

4. U.S. Food and Drug Administration. (2015). Code of Federal Regulations, Title 21, Part 314: Applications for FDA approval to market a new drug. https://www.ecfr.gov/current/title-21/chapter-I/subchapter-D/part-314